Clinical decision support to aid watchful waiting of cardiovascular disease

A system comprising:

• a memory configured to store instructions;
• and
• one or more processors configured to execute the instructions to perform operations comprising:
• inputting, to an estimation model, non-invasively obtained data related to a plaque from a patient;
• generating virtual 'omics data that include estimated pathway activations or molecule levels, or both, of the patient, by applying the estimation model to the non-invasively obtained data from the patient;
• updating an in silico systems biology model using the generated virtual 'omics data to generate an in silico patient-specific systems biology model, wherein
• (i) the in silico systems biology model comprises a set of networks, wherein each network comprises a plurality of nodes, each node representing a baseline level of a molecule or pathway, and a plurality of edges between pairs of nodes, each edge representing a node-node interaction,
• (ii) at least two of the nodes of the plurality of nodes in each network represent molecules or pathways whose levels are affected by an atherosclerotic cardiovascular disease, and
• (iii) at least one network of the set of networks includes a disease-associated pathway activation or molecule level, or both, for each of the nodes in the network;
• perturbing the in silico patient-specific systems biology model to simulate, for the patient, a therapeutic effect of one or more pharmaceutical agents singly or in combination;
• and
• providing an output indicating a level of improvement in the atherosclerotic cardiovascular disease for the patient and a recommendation supporting a clinical decision to monitor patient status without introducing new treatment if the patient's atherosclerosis is at stable levels.

One or more non-transitory computer-readable media storing instructions that are executable by one or more processing devices, and upon such execution cause the one or more processing devices to perform operations comprising:

• inputting, to an estimation model, non-invasively obtained data related to a plaque from a patient;
• generating virtual 'omics data that include estimated pathway activations or molecule levels, or both, of the patient, by applying the estimation model to the non-invasively obtained data related from the patient;
• updating an in silico systems biology model using the generated virtual 'omics data to generate an in silico patient-specific systems biology model, wherein
• (i) the in silico systems biology model comprises a set of networks, wherein each network comprises a plurality of nodes, each node representing a baseline level of a molecule or pathway, and a plurality of edges between pairs of nodes, each edge representing a node-node interaction,
• (ii) at least two of the nodes of the plurality of nodes in each network represent proteins whose levels are affected by an atherosclerotic cardiovascular disease, and
• (iii) at least one network of the set of networks includes a disease-associated pathway activation or molecule level, or both, for each of the nodes in the network;
• perturbing the in silico patient-specific systems biology model to simulate, for the patient, a therapeutic effect of one or more pharmaceutical agents singly or in combination;
• and
• providing an output indicating a level of improvement in the atherosclerotic cardiovascular disease for the patient and a recommendation supporting a clinical decision to monitor patient status without introducing new treatment if the patient's atherosclerosis is at stable levels.